http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Multiple Low Dose Streptozotocin으로 유도된 당뇨 흰쥐에서 투여 시기에 따른 인삼의 항당뇨 활성 비교
박경수(Kyeong Soo Park),이동억(Dong Eok Lee),성종환(Jong Hwan Sung),정성현(Sung Hyun Chung) 고려인삼학회 2002 Journal of Ginseng Research Vol.26 No.4
In this study, we like to examine whether Panax ginseng water extract (PGWE) exerts antidiabetic activities in prevention and treatment modes in multiple low dose (MLD) streptozotocin (STZ) (20 mg/kg i.p injection for 5 days) induced diabetic SD rats. In the prevention mode, 150 mg/kg of GRWE was administered intraperitoneally with STZ for 3 weeks, and this group is called CO150. In the treatment mode, we started to administer the same dose of PGWE on day 8 and for 3 weeks, and this group is called POST150. PGWE exerted significant hypoglycemic activities in both prevention (normal control, 97±6 mg/dl; diabetic control, 331±23; CO150, 211±37) and treatment groups (normal control,128±4 mg/dl; diabetic control, 392±33; POST150, 263±44). Of great importance is the fact that plasma insulin levels in both groups were markedly increased as compared to the diabetic control (normal control, 428.7±62.1 pg/dl; diabetic control, 167.0±91.7; CO150, 377.6±68.7 in prevention mode, and in treatment mode normal control 417.9±<br/> 84.6 pg/dl; diabetic control, 166.1±104.7; POST150, 315.2±47.4). Blood glucose levels were closely associated with plasma insulin levels, and this result may suggest that PGWE showed the activity to enhance insulin secretion as well as preventing destruction of pancreatic islet cells. Food and water intakes were also determined at the last week of treatment in both groups. Characteristic symptoms of diabetes were significantly improved in both groups. In the prevention mode, water intake (ml/rat/day) in normal control was increased from 30.6±1.5 to 122.2±3.4 in diabetic control rats. In the CO150-treated group, water intake was dramatically reduced to 68.3±4.4 (p<0.001 vs. diabetic control). In the treatment mode, POST-treated group also reduced the water intake from 128.9±2.2 to 113.3±1.7. Taken together, our data suggest<br/> that PGWE showed comparable antidiabetic activities in prevention and treatment modes. Therefore, PGWE may have a potential as a prophylactic as well as therapeutic agent for type 2 diabetes mellitus (T2DM).
새로운 유전자 재조합 기술에 의하여 생산된 Erythropoietin 의 일반약리작용
김현수(Hyun Su Kim),박관하(Kwan Ha Park),김달현(Dal Hyun Kim),이동억(Dong Eok Lee),김영훈(Young Hoon Kim),정성목(Seong Mok Jeong),임동문(Dong Moon Lim),조효진(Hyo Jin Cho),정재경(Jae Kyung Jung) 한국응용약물학회 1994 Biomolecules & Therapeutics(구 응용약물학회지) Vol.2 No.4
The general pharmacological properties of EPO were investigated in various animals administering intravenously and in vitro system. The results were as follows. 1. Central nervous system: EPO at doses of 70, 700, 7000 U/kg showed no effect in mice on general behavior, on strychnine- an ntetrazol-induced convulsion and on acetic acid-induced writhing syndrome. The hexobarbital-induced sle g time in mice was slightly reduced by EPO at a dose of 7000 U/kg but did not change at doses of 70, 700 U/kg. The body temperature in rats was slightly decreased by EPO at doses of 700, 7,000 U/kg but the change was in normal physiological range. 2. Respiratory and cardiovascular system: EPO showed no effect on respiratory rate, blood pressure, heart rate, femoral blood flow, and electrocardiogram in anesthetized dogs at doses of 70, 700, 7000 U/kg. 3. Smooth muscle: EPO at concentrations of 70, 700 U/ml had no effect on the contractile response of isolated guinea pig ileum to histamine and acetylcholine. 4. Water and electrolytes excretion: EPO at dose above 700 U/kg increased urine volume in rats but did not affect the concentrations of Na^+, K^+, Cl^- in urine. 5. Gastrointestinal system: EPO(70, 700, 7000 U/kg) had no effect on the intestinal charcoal meal propulsion in mice. 6. Blood coagulation system: The administration of EPO(70, 700, 7000 U/kg) had no effect on the plasma prothrombin time(PT) and activated partial thromboplastin time(APTT) in mice. Platelet aggregation induced by ADP and collagen was not influenced by EPO(70 U/ml, 700 U/ml). The overall results obtained indicated that EPO exerts almost no serious pharmacological effect even at a 100-fold clinical dose(7000 U/kg).
CHO 세포에서 생산된 재조합 Erythropoietin ( EPO ) 의 약효
김현수(Hyun Su Kim),박관하(Kwan Ha Park),김달현(Dal Hyun Kim),이동억(Dong Eok Lee),김석준(Suk Joon Kim),하병집(Byung Jhip Ha),오명석(Myung Suk Oh) 한국응용약물학회 1994 Biomolecules & Therapeutics(구 응용약물학회지) Vol.2 No.4
In vivo activity of recombinant human erythropoietin (rh-EPO) has been examined using polycythemic model in mice and acute hemorrhage model in rats. The number of reticulocytes in blood stream was increased after a single injection of rh-EPO depending on the dosage of rh-EPO in polycythemy model. It seemed that optimal dose of rh-EPO for polycythemic mice was around 1-10 U/kg. Rh-EPO also showed the effectiveness for increase of reticulocyte numbers both in male and female rats after bleeding. The number of reticulocytes and the change of hemoglobin concentration in the blood stream of normal rats has been examined after injection of rh-EPO. The maximum value of reticulocyte was observed on the 6th day of the injection in these normal rats. In addition, the increase of reticulocyte and the concentration of hemoglobin were dependent on the dosage of rh-EPO. The increase of hemoglobin concentration was continued to the 9th day after injection. In this study, the efficacy of rh-EPO was confirmed in both mice and rats.
기니픽과 마우스에서 CFC-101 ( 녹농균 백신 ) 의 항원성시험
선우연(Woo Yearn Sun),한형미(Hyung Mee Han),김현수(Hyun Su Kim),백남진(Nam Jin Baek),김달현(Dal Hyun Kim),이동억(Dong Eok Lee),정승태(Seung Tae Chung),김필선(Pil Sun Kim) 한국응용약물학회 1994 Biomolecules & Therapeutics(구 응용약물학회지) Vol.2 No.4
As a part of the safety evaluation of Pseudomonas vaccine(CFC-101), antigenicity tests were carried out in guinea pigs and mice. In active systemic anaphylaxis(ASA) test, guinea pigs showed no sign or only moderate sign(1/5) when sensitized and challenged with up to 200 ㎍/㎏. In homologous passive cutaneous anaphylaxis(PCA) test using guinea pigs, inoculation of CFC-101 alone did not produce CFC-101-specific antibody. When inoculated with 200 ㎍/㎏ plus adjuvant, challenge of 200 ㎍/㎏ produced PCA titer of 32(5/5) but challenge of 20 ㎍/㎏ did not produce CFC-101-specific antibody. In heterologous PCA test using mice, CFC-101-specific antibody was not detected when sensitized with CFC-101 alone. Some animals(3/12) showed positive PCA response when inoculated with 200 ㎍/㎏ plus alum. In passive hemagglutination (PHA) test, although no antibody was detected at 20 ㎍/㎏, inoculation of 200 ㎍/㎏ alone or with alum produced positive response in all animals. This result has already been predicted because CFC-101 is a vaccine developed for the purpose of immunization. From the above results, it can be concluded that there is no adverse antigenic potential up to 10 times clinical dose of 200 ㎍/㎏.